NEW YORK (GenomeWeb News) – SuperGen said today that it will screen epigenetic targets for cancer drugs for GlaxoSmithKline, under an agreement announced today.

The Dublin, Calif.-based drug screening and development firm said that it will receive $5 million up front, which includes a $3 million investment from the UK drug maker. It also said that milestone and royalty payments from GSK for development and commercialization could potentially surpass $375 million, and it could also receive tiered royalties reaching double-digits on products derived from the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.